Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Drotrecogin Alfa (Activated) Treatment in Severe Sepsis With Vasopressor-Dependent Hypotension
2004-001319-71Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of drotrecogin alfa in sepsis and septic shock, sponsored by Eli Lilly and Company. Primary endpoint: Time to resolution of vasopressor-dependent hypotension. Started Apr 2012; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2004-001319-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001319-71.